Inactive Instrument

Biosyent Inc. Share Price Toronto S.E.

Equities

RX

CA0906901081

Pharmaceuticals

Financials

Sales 2024 * 3.5Cr 2.56Cr 214.02Cr Sales 2025 * 3.87Cr 2.83Cr 236.65Cr Capitalization 12Cr 8.47Cr 708.77Cr
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 3.31 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 3 x
P/E ratio 2024 *
18.2 x
P/E ratio 2025 *
15.9 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 60.64%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 64 01/96/01
Director of Finance/CFO - 10/18/10
Chief Tech/Sci/R&D Officer - 01/14/01
Members of the board TitleAgeSince
Director/Board Member 53 08/18/08
Chief Executive Officer 64 01/96/01
Director/Board Member 60 01/02/01
More insiders
BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.
More about the company
1st Jan change Capi.
+55.35% 82TCr
+32.40% 60TCr
-0.10% 38TCr
+15.47% 32TCr
+13.10% 31TCr
+16.25% 25TCr
+14.52% 23TCr
+16.54% 18TCr
+4.31% 17TCr
Other Pharmaceuticals